Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial.

@article{Lindsay2017AutologousST,
  title={Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial.},
  author={James Oliver Lindsay and Mathieu Allez and Miranda M Clark and Myriam Labopin and Elenor Ricart and Gerhard Rogler and Montserrat Comas Rovira and Jack Satsangi and Dominique Farge and Christopher John Hawkey},
  journal={The lancet. Gastroenterology & hepatology},
  year={2017},
  volume={2 6},
  pages={
          399-406
        }
}
BACKGROUND The randomised controlled ASTIC trial showed no benefit of mobilisation and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisation followed by conventional therapy using a stringent primary endpoint (steroid-free clinical remission for 3 months with no endoscopic or radiological evidence of intestinal inflammation) in patients with treatment-refractory Crohn's disease. We now assess HSCT in patients enrolled in the ASTIC trial using endpoints that are… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 15 times over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…